Activation of the MDR1 Upstream Promoter in Breast Carcinoma As A Surrogate for Metastatic Invasion

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2776-2783

  Raguz, Selina ^a   De Bella, Manuela Tamburo ^a   Tripuraneni, Gopichani ^a   Slade, Martin J ^a   Higgins, Christopher F ^a   Coombes, R Charles ^a   Yagüe, Ernesto ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DISEASE MARKER; GENE ACTIVATION; GENE INACTIVATION; GENE LOCUS; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; BLOTTING, SOUTHERN; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; EPITHELIAL CELLS; FEMALE; GENES, MDR; HUMANS; LEUKEMIA, LYMPHOCYTIC; LYMPHATIC METASTASIS; MIDDLE AGED; MODELS, GENETIC; NEOPLASM METASTASIS; P-GLYCOPROTEIN; PHENOTYPE; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 1942438172     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0517     Document Type: Article

References (54)

1. Chang J, Clark GM, Allred DC, et al. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer (Phila) 2003;97:545-53.
2. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001;11:339-52.
3. Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 2001;34:347-52.
4. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002;8:1167-71.
5. Adeyinka A, Nui Y, Cherlet T, et al. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 2002;8:1747-53.
6. Shen Z, Wen XF, Lan F, Shen ZZ, Shao ZM. The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res 2002;8:2085-90.
7. Chang A, Yousef GM, Scorilas A, et al. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer 2002;86:1457-64.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
9. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001;7:548-52.
10. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
11. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond) 2002;415:530-6.
12. Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer 2003;103:149-52.
13. Jiang WG, Martin TA, Mansel RE. Molecular detection of micrometastasis in breast cancer. Crit Rev Oncol Hematol 2002;43:13-31.
14. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
15. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst (Bethesda) 1997;89:917-31.
16. Boshart M, Gissmann L, Ikenberg H, et al. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984;3:1151-7.
17. Ueda K, Clark DP, Chen CJ, et al. The human multidrug resistance (mdr1) gene, cDNA cloning and transcription initiation. J Biol Chem 1987;262:505-8.
18. Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 1987;262:17432-6.
19. Chen CJ, Clark D, Ueda K, et al. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990;265:506-14.
20. Rothenberg ML, Mickley LA, Cole DE, et al. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 1989;74:1388-95.
21. Gazet JC, Coombes RC, Ford HT, et al. Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer 1996;73:758-62.
22. Kothari MS, Ali S, Buluwela L, et al. Purified malignant mammary epithelial cells maintain hormone responsiveness in culture. Br J Cancer 2003;88:1071-6.
23. Fairchild CR, Ivy SP, Kao-Shan CS, et al. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res 1987;47:5141-8.
24. Gioanni J, Le Francois D, Zanghellini E, et al. Establishment and characterisation of a new tumorigenic cell line with a normal karyotype derived from a human breast adenocarcinoma. Br J Cancer 1990;62:8-13.
25. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lakins J, Lupu R. Expression and regulation of estrogen receptor β in human breast tumors and cell lines. Oncol Rep 2000;7:157-67.
26. Drexler HG. The leukemia-lymphoma cell line facts book. London: Academic Press; 2001.
27. Yague E, Armesilla AL, Harrison G, et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003;278:10344-52.
28. Shen DW, Cardarelli C, Hwang J, et al. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, Adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 1986;261:7762-70.
29. Dillon N, Grosveld F. Transcriptional analysis using transgenic animals. In: Hames BD, Higgins SJ, editors. Gene transcription: a practical approach. Oxford, United Kingdom: Oxford University Press; 1993. p. 153-88.
30. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:7160-4.
31. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
32. Roninson IB, Chin JE, Choi KG, et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 1986;83:4538-42.
33. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:2729-34.
34. Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 1990;43:213-9.
35. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature (Lond) 2000;406:747-52.
36. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-8.
37. Van der Bliek AM, Baas F, Van der Velde-Koerts T, et al. Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res 1988;48:5927-32.
38. Knuutila S, Bjorkqvist AM, Autio K, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998;152:1107-23.
39. Knuutila S, Autio K, Aalto Y. Online access to CGH data of DNA sequence copy number changes. Am J Pathol 2000;157:689.
40. Speicher MR, Howe C, Crotty P, et al. Comparative genomic hybridization detects novel deletions and amplifications in head and neck squamous cell carcinomas. Cancer Res 1995;55:1010-3.
41. Schrock E, Thiel G, Lozanova T, et al. Comparative genomic hybridization of human malignant gliomas reveals multiple amplification sites and nonrandom chromosomal gains and losses. Am J Pathol 1994;144:1203-18.
42. Knutsen T, Mickley LA, Ried T, et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 1998;23:44-54.
43. Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 1989;49:5829-36.
44. Nyce JW. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 1997;386:153-61.
45. Counts JL, Goodman JI. Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion. Prog Clin Biol Res 1995;391:81-101.
46. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-13.
47. Bernardino J, Roux C, Almeida A, et al. DNA hypomethylation in breast cancer: an independent parameter of tumor progression? Cancer Genet Cytogenet 1997;97:83-9.
48. Soares J, Pinto AE, Cunha CV, et al. Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer (Lond) 1999;85:112-8.
49. Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 1998;92:4296-307.
50. de Launoit Y, Chotteau-Lelievre A, Beaudoin C, et al. The PEA3 group of ETS-related transcription factors. Role in breast cancer metastasis. Adv Exp Med Biol 2000;480:107-16.
51. Kaye SB. Multidrug resistance in breast cancer: is the jury in yet? J Natl Cancer Inst (Bethesda) 1997;89:902-3.
52. Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003;9:827-36.
53. Yang J-M, Vassil A, Hait WN. Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells. Biochem Pharmacol 2002;63:959-66.
54. Linn SC, Honkoop AH, Hoekman K, et al. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996;74:63-8.